Re: Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination.
Giorgi Rossi
Paolo
P
Zappa
Marco
M
D052685:Alphapapillomavirus / Q000302:isolation & purification*; D003362:Cost-Benefit Analysis; D004279:DNA, Viral / Q000302:isolation & purification*; D019049:Developed Countries; D005260:Female; D052162:Human papillomavirus 16 / Q000276:immunology; D052161:Human papillomavirus 18 / Q000276:immunology; D006801:Humans; D015994:Incidence; D008403:Mass Screening / Q000191:economics* / Q000379:methods*; D053918:Papillomavirus Vaccines / Q000008:administration & dosage*; D016312:Treatment Refusal; D002583:Uterine Cervical Neoplasms / Q000191:economics* / Q000453:epidemiology / Q000517:prevention & control / Q000821:virology
D004279:DNA, Viral; D053918:Papillomavirus Vaccines